All In Biotech

Drug Trial Radar · NCT04639466

A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection

Phase 1/2 Dose Escalation Study To Evaluate the Safety and Biologically Effective Dose of GEO-CM04S1, a Synthetic MVA-based SARS-CoV-2 Vaccine, Administered as One or Two Injections or as a Booster to Healthy Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 119 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

119

Actual

Start

Nov 19, 2020

Primary completion

Oct 31, 2025

Study completion Dec 3, 2025

Sponsor

Lead sponsor
GeoVax, Inc.Industry
Sponsor type
Industry
First posted
Nov 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase I trial evaluates the side effects and best dose of GEO-CM04S1 (previously designated as COH04S1), a synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine, for the prevention of COVID-19 infection. COVID-19 infection is caused by the SARS-CoV-2 virus. SARS-CoV-2 has demonstrated the capability to spread rapidly, leading to significant impacts on healthcare systems and causing societal disruption. GEO-CM04S1 was created by placing small pieces of SARS-CoV-2 DNA (the chemical form of genes) into synthetic MVA, which may be able to induce immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The purpose of the Phase 1 study is to determine the safety and the optimal dose of the GEO-CM04S1 vaccine. The Phase 2 study is designed as a multi-center, double-blind, randomized, parallel, study to evaluate the safety profile of 2 dose levels of GEO-CM04S1 as a single booster shot to assess the immune response measured by the fold-increase in antibody against SARS-CoV-2 Spike protein at day 28 post-injection among healthy adult volunteers.

Conditions

  • COVID-19 Infection

Interventions

  • Placebo AdministrationDrug

    Given IM in the non-dominant upper arm

  • Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1Biological

    Given IM in the non-dominant upper arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (Phase I)Time frame: Up to 365 days
  2. Incidence of adverse events (Phase II)Time frame: Within the first 7 days following booster injection
  3. Antibody levels to SARS CoV-2 Spike protein (Phase II)Time frame: Up to 365 days
  4. Fold increase of Spike IgG levels (Phase II)Time frame: At 28 days post-injection

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • EmVenio Research

    Claremont, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Millennium Clinical Trials

    Thousand Oaks, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.